Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GLL 398 is an orally active and selective degrader of estrogen receptor with an IC50 of 1.14 nM. GLL 398 blocks tumor growth in xenograft breast cancer models.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | $ 195.00 | |
5 mg | Inquiry | $ 437.00 | |
10 mg | Inquiry | $ 655.00 | |
25 mg | Inquiry | $ 1,178.00 | |
50 mg | Inquiry | $ 1,768.00 | |
100 mg | Inquiry | $ 2,652.00 | |
200 mg | Inquiry | $ 3,978.00 | |
1 mL * 10 mM (in DMSO) | Inquiry | $ 447.00 |
Description | GLL 398 is an orally active and selective degrader of estrogen receptor with an IC50 of 1.14 nM. GLL 398 blocks tumor growth in xenograft breast cancer models. |
In vitro | GLL398 exhibits a strong dose-dependent binding profile for the estrogen receptor with a Y537S point mutation with an IC50 of 29.5 nM[1]. |
Molecular Weight | 398.26 |
Formula | C25H23BO4 |
CAS No. | 2077980-80-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 245 mg/mL (615.18 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GLL 398 2077980-80-2 Endocrinology/Hormones Estrogen Receptor/ERR mutant inhibit ESR1 Y537S selective estrogen receptor degrader GLL-398 GLL398 Inhibitor SERD breast cancer inhibitor